Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

January 13, 2022 updated by: Eisai Co., Ltd.

A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
      • Aomori, Japan
        • 1022 Eisai Trial Site
      • Chiba, Japan
        • 1010 Eisai Trial Site
      • Fukuoka, Japan
        • 1012 Eisai Trial Site
      • Fukuoka, Japan
        • 1016 Eisai Trial Site
      • Hiroshima, Japan
        • 1011 Eisai Trial Site
      • Kumamoto, Japan
        • 1024 Eisai Trial Site
      • Kyoto, Japan
        • 1003 Eisai Trial Site
      • Kyoto, Japan
        • 1008 Eisai Trial Site
      • Nagasaki, Japan
        • 1023 Eisai Trial Site
      • Okayama, Japan
        • 1009 Eisai Trial Site
      • Osaka, Japan
        • 1015 Eisai Trial Site
      • Yamagata, Japan
        • 1018 Eisai Trial Site
    • Aichi
      • Nagoya, Aichi, Japan
        • 1004 Eisai Trial Site
      • Nagoya, Aichi, Japan
        • 1029 Eisai Trial Site
    • Gunma
      • Ota, Gunma, Japan
        • 1020 Eisai Trial Site
    • Hokkaido
      • Sapporo, Hokkaido, Japan
        • 1007 Eisai Trial Site
    • Hyogo
      • Kobe, Hyogo, Japan
        • 1019 Eisai Trial Site
    • Ibaraki
      • Tsukuba, Ibaraki, Japan
        • 1005 Eisai Trial Site
    • Kanagawa
      • Isehara, Kanagawa, Japan
        • 1002 Eisai Trial Site
      • Yokohama, Kanagawa, Japan
        • 1028 Eisai Trial Site
    • Miyagi
      • Sendai, Miyagi, Japan
        • 1021 Eisai Trial Site
    • Osaka
      • Osakasayama, Osaka, Japan
        • 1013 Eisai Trial Site
      • Suita, Osaka, Japan
        • 1006 Eisai Trial Site
    • Shizuoka
      • Suntou-gun, Shizuoka, Japan
        • 1027 Eisai Trial Site
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan
        • 1026 Eisai Trial Site
      • Chuo-ku, Tokyo, Japan
        • 1001 Eisai Trial Site
      • Koto-ku, Tokyo, Japan
        • 1025 Eisai Trial Site
      • Minato-ku, Tokyo, Japan
        • 1017 Eisai Trial Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma (NHL) as follows:

    • Cohort 1: Follicular lymphoma (FL)
    • Cohort 2: Diffuse large B-cell lymphoma (including primary mediastinal B-cell lymphoma and transformed FL)
  • Participants who have confirmed EZH2 gene mutation of tumor in central laboratory
  • Participants who have measurable disease
  • Participants who had previous therapy with systemic chemotherapy and/or antibody therapy and for which no standard therapy exists
  • Participants who had progressive disease or did not have response (complete response or partial response) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
  • Participants with Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants with life expectancy of ≥3 months from starting study drug administration
  • Participants with adequate renal, liver, and bone marrow function
  • Male and female participants ≥20 years of age at the time of informed consent
  • Participants who has provided written consent to participate in the study

Exclusion Criteria:

  • Participants with prior exposure to EZH2 inhibitor
  • Participants with a history or a presence of central nerves invasion
  • Participants with malignant pleural effusion, cardiac effusion, or ascites retention
  • Participants with allogeneic stem cell transplantation
  • Participants with medical need for the continued use of potent inhibitors of Cytochrome P450 3A (CYP3A)or potent inducer of CYP3A (including St. John's wort)

  • Participants with significant cardiovascular impairment

    · Participants with prolongation of corrected QT interval using Fridericia's formula to > 480 milliseconds (msec)

  • Participants with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug
  • Participants with complications of hepatic cirrhosis, interstitial pneumonia or pulmonary fibrosis
  • Participants with active infection requiring systemic therapy
  • Women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later (for males 90 days later) from last administration of study drug
  • Woman who are pregnant or breastfeeding
  • Participants who were deemed as inappropriate to participate in the study by the investigator or sub-investigator
  • Have any prior history of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia or myeloid malignancies, including myelodysplastic syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FL with EZH2 gene mutation
Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
Drug: Tazemetostat
Tazemetostat will be provided as a 200 mg oral tablet.
Experimental: DLBCL with EZH2 gene mutation
Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
Drug: Tazemetostat
Tazemetostat will be provided as a 200 mg oral tablet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR)
Time Frame: From administration of the first dose of the study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent, or study termination (up to 30 months)
ORR is defined as the number of participants with a best overall response of complete response or partial response.
From administration of the first dose of the study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent, or study termination (up to 30 months)

Secondary Outcome Measures

Outcome Measure
Time Frame
Progression-free survival (PFS)
Time Frame: From administration of the first dose of the study drug to the date of the first event (disease progression, death, etc.) (up to 30 months)
From administration of the first dose of the study drug to the date of the first event (disease progression, death, etc.) (up to 30 months)
Duration of response (DOR)
Time Frame: From confirmation of the first response to the date of the first event (disease progression, death, etc.) (up to 30 months)
From confirmation of the first response to the date of the first event (disease progression, death, etc.) (up to 30 months)
Time to response (TTR)
Time Frame: From administration of the first dose of the study drug to confirmation of the first response (up to 30 months)
From administration of the first dose of the study drug to confirmation of the first response (up to 30 months)
Number of participants with any adverse event, as an assessment of safety
Time Frame: From administration of the first dose of the study drug to 30 days after the last dose (up to 30 months)
From administration of the first dose of the study drug to 30 days after the last dose (up to 30 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eisai Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 9, 2018

Primary Completion (Actual)

December 17, 2021

Study Completion (Actual)

December 17, 2021

Study Registration Dates

First Submitted

March 6, 2018

First Submitted That Met QC Criteria

March 6, 2018

First Posted (Actual)

March 7, 2018

Study Record Updates

Last Update Posted (Actual)

January 14, 2022

Last Update Submitted That Met QC Criteria

January 13, 2022

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E7438-J081-206

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Trials on Tazemetostat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe